Bausch Health Cos Inc. (NYSE:BHC) Given Average Rating of "Reduce" by Analysts

Shares of Bausch Health Cos Inc. (NYSE:BHC - Get Free Report) have earned a consensus rating of "Reduce" from the seven brokerages that are currently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation and six have given a hold recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $7.42.

A number of equities analysts recently weighed in on the stock. Wall Street Zen downgraded shares of Bausch Health Cos from a "buy" rating to a "hold" rating in a research note on Saturday, May 10th. Royal Bank Of Canada lifted their target price on shares of Bausch Health Cos from $8.50 to $10.00 and gave the stock a "sector perform" rating in a research note on Friday, May 2nd.

Bausch Health Cos Price Performance

NYSE BHC traded up $0.46 during mid-day trading on Friday, reaching $6.19. 4,642,553 shares of the stock were exchanged, compared to its average volume of 2,634,433. Bausch Health Cos has a one year low of $3.96 and a one year high of $9.85. The stock has a 50 day simple moving average of $4.91 and a 200-day simple moving average of $6.38. The stock has a market cap of $2.29 billion, a P/E ratio of -56.30 and a beta of 0.28.

Insider Buying and Selling at Bausch Health Cos

In related news, Director John Paulson purchased 1,029,098 shares of the firm's stock in a transaction on Wednesday, June 11th. The stock was purchased at an average cost of $5.24 per share, with a total value of $5,392,473.52. Following the completion of the purchase, the director now owns 28,222,267 shares in the company, valued at approximately $147,884,679.08. This trade represents a 3.78% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders purchased 6,352,667 shares of company stock valued at $35,870,767. Corporate insiders own 8.05% of the company's stock.

Institutional Investors Weigh In On Bausch Health Cos

Hedge funds and other institutional investors have recently bought and sold shares of the stock. SBI Securities Co. Ltd. grew its holdings in shares of Bausch Health Cos by 244.2% during the first quarter. SBI Securities Co. Ltd. now owns 4,230 shares of the company's stock valued at $27,000 after buying an additional 3,001 shares during the last quarter. Cary Street Partners Financial LLC acquired a new position in shares of Bausch Health Cos during the first quarter valued at about $27,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Bausch Health Cos during the first quarter valued at about $27,000. Mountain Hill Investment Partners Corp. acquired a new position in shares of Bausch Health Cos during the fourth quarter valued at about $56,000. Finally, Wealthquest Corp acquired a new position in shares of Bausch Health Cos during the first quarter valued at about $58,000. 78.65% of the stock is owned by institutional investors.

Bausch Health Cos Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.